Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Supplementary Information for Financial Results Q3 FY12/25
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2025
Supplementary Information for Financial Results Q2 FY12/25
Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2025
Non-Consolidated Financial Results (Japanese GAAP) for the Three Months Ended March 31,2025
Supplementary Information for Financial Results Q1 FY12/25
[Updated] Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2024
Announcement of a collaborative exploratory research agreement with OmniAb, Inc.
Supplementary Information for Financial Results FY12/24
Non-Consolidated Financial Results (Japanese GAAP) for the Fiscal Year Ended December 31, 2024
Announcement of Paper Publication on Cancer Immunotherapy Using Tribody Technology
Announcement of Paper Publication on the First Part of the CBA-1205 Phase I Clinical Study
Announcement of Paper Publication on CBA-1205 Non-Clinical Data
Extension of the Master Services Agreement with Chugai Pharmaceutical Co., Ltd.
[Revised] Chiome Announces Exclusive Licensing Agreement for Anti-CX3CR1 Antibody
Chiome Announces Exclusive Licensing Agreement for Anti-CX3CR1 Antibody
Non-Consolidated Financial Results (Japanese GAAP) for the Nine Months Ended September 30, 2024
Supplementary Information for Financial Results Q3 FY12/24